Francesca Palandri: Prioritizing Anemia Matters in Myelofibrosis
Francesca Palandri, Hematologist at Sant’Orsola-Malpighi Polyclinic – Bologna University Hospital, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in Clinical Lymphoma, Myeloma and Leukemia, adding:
“Prioritizing anemia matters in myelofibrosis.
Happy to share our latest subgroup analysis from the phase III SIMPLIFY-1 trial, now published in Clinical Lymphoma, Myeloma Leukemia.
We examined momelotinib vs. ruxolitinib in JAK inhibitor–naive myelofibrosis patients with anemia (Hb 10 g/dL).
Key Findings:
- Momelotinib achieved higher dual response rates (spleen reduction and transfusion independence) vs. ruxolitinib: 27% vs. 7%
- In patients with platelets 200 × 10⁹/L, momelotinib showed superior spleen response: 39% vs. 17%
- Transfusion independence correlated with significantly improved overall survival (HR 0.25–0.40)
Prioritizing transfusion independence in anemic MF patients and suggest momelotinib may be preferred in those with lower platelet counts.
Honored to serve as first author of this collaborative work together with an outstanding group of colleagues.
A big thank-you to all my colleagues at IRCCS Policlinico di Sant’Orsola – Azienda Ospedaliero Universitaria di Bologna.”
Title: Spleen Volume Reduction and Transfusion Independence With Momelotinib Versus Ruxolitinib and Associated Overall Survival With Momelotinib in JAK Inhibitor-Naive Patients With Myelofibrosis and Anemia: Subgroup Analyses of SIMPLIFY-1
Authors: Francesca Palandri, Nicolaas P M Schaap, Jerome Rey, Nikolas von Bubnoff, Andreas Reiter, Juan Carlos Hernandez-Boluda, Timothy Devos, Lars Nilsson, Bethan Psaila, Donal P McLornan, Bryan Strouse, Shiyuan Zhang, Bharat Patel, Jessica Lim, Dwaipayan Patnaik, Stephen T Oh
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 10, 2026, 16:28Can the VWF to ADAMTS-13 Ratio Predict Mortality in Sepsis-Induced Coagulopathy? – RPTH Journal
-
Nov 10, 2026, 16:28Ruth Willems: PhD Defence at Maastricht University on Thrombosis and Bleeding in HPB Disease
-
Nov 10, 2026, 16:09Edward Lee Carter: Factor XIa Inhibition Enters Clinical Practice
-
Nov 10, 2026, 16:08Edward C.C. Wong: Deriving Ferritin Cutoffs for Iron Deficiency Using RBC Parameters
-
Nov 10, 2026, 16:07Milad Abdalla: Decoding Hemoglobin Electrophoresis – A Practical Diagnostic Reference
-
Nov 10, 2026, 15:13Wolfgang Miesbach: Nonviral Gene Therapy for Haemophilia A Using Lipid Nanoparticles
-
Nov 10, 2026, 15:06Dahra Teles: First Speaking Experience at HEMO 2026 on First-Line Multiple Myeloma Treatment
-
Nov 10, 2026, 14:55Yazan Abou-Ismail: First FDA-Approved Factor XIa Inhibitor for Stroke Prevention
-
Nov 10, 2026, 14:49Ifeanyichukwu Ifechidere: The Role of Coagulation in Anaesthesia and Surgery